Loading...
XNASTHTX
Market cap176mUSD
, Last price  
0.00USD
Name

Theratechnologies Inc

Chart & Performance

D1W1MN
XNAS:THTX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
%
Shrs. gr., 5y
6.76%
Rev. gr., 5y
13.17%
Revenues
82m
+2.13%
13,657,2747,131,3925,899,72522,549,76227,604,28333,225,07344,054,62363,216,00066,053,00069,823,00080,057,00081,764,000
Net income
-24m
L-49.28%
-14,032,756-3,828,650-9,237,8201,178,694305,291-14,301,106-4,524,114-12,496,000-22,667,000-31,725,000-47,237,000-23,957,000
CFO
-6m
L-61.35%
-15,738,028-7,311,730-7,045,1415,316,5062,003,7521,902,938-334,060-3,391,000-13,554,000-14,477,000-14,692,000-5,678,000
Earnings
Feb 19, 2025

Profile

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
URL
http://www.theratech.com/
IPO date
Dec 21, 1993
Employees
144
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑112015‑11
Income
Revenues
81,764
2.13%
80,057
14.66%
Cost of revenue
92,391
119,965
Unusual Expense (Income)
NOPBT
(10,627)
(39,908)
NOPBT Margin
Operating Taxes
421
443
Tax Rate
NOPAT
(11,048)
(40,351)
Net income
(23,957)
-49.28%
(47,237)
48.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,160
2,960
BB yield
Debt
Debt current
7,707
65,265
Long-term debt
52,255
3,368
Deferred revenue
Other long-term liabilities
84
106
Net debt
19,103
34,218
Cash flow
Cash from operating activities
(5,678)
(14,692)
CAPEX
(318)
(985)
Cash from investing activities
1,108
8,682
Cash from financing activities
14,775
9,656
FCF
(9,935)
(33,645)
Balance
Cash
40,854
33,070
Long term investments
5
1,345
Excess cash
36,770
30,412
Stockholders' equity
(44,048)
(43,513)
Invested Capital
82,230
87,365
ROIC
ROCE
EV
Common stock shares outstanding
26,332
23,813
Price
Market cap
EV
EBITDA
(7,326)
(27,437)
EV/EBITDA
Interest
10,546
6,497
Interest/NOPBT